Last 12 months
Inside the activity.
0 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:20 UTC |
Raben DavidChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 575,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001746473-26-000117 · wk-form4_1790972430.xml · derivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2036-10-01 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to such option vest and become exercisable on September 30, 2027, and the remaining seventy-five percent (75%) of the shares subject to the option vest and become exercisable in substantially equal installments thereafter on each monthly anniversary of September 30, 2027 (or if there is no corresponding day in any such month, on the last day of each month) over three (3) years, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:32 UTC |
Iannone RobertDirector
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001737329-26-000013 · wk-form4_1783974746.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:32 UTC |
Borellini FlaviaDirector
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001867426-26-000004 · wk-form4_1783974731.xml · derivative · entry 1 Borellini Flavia · CIK 0001867426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:01 UTC |
Krognes Steve E.Director
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000102 · wk-form4_1781298070.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:01 UTC |
MCCOURT Thomas ADirector
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000103 · wk-form4_1781298078.xml · derivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:00 UTC |
Huh HoyoungDirector
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000100 · wk-form4_1781298056.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:01 UTC |
CROWELL GAYLE ADirector
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000104 · wk-form4_1781298082.xml · derivative · entry 1 CROWELL GAYLE A · CIK 0001250893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:01 UTC |
Curnutte John TDirector
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000101 · wk-form4_1781298064.xml · derivative · entry 1 Curnutte John T · CIK 0001574589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:00 UTC |
Cline Darren SDirector
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000099 · wk-form4_1781298048.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 113,300 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 14 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,300 Underlying: Common Stock · 113,300 shares Expires 2035-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 113,300 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 13 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,300 shares Expires 2035-01-23 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 110,500 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 12 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,500 Underlying: Common Stock · 110,500 shares Expires 2034-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 110,500 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 11 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,500 shares Expires 2034-01-23 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 76,200 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 10 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,200 Underlying: Common Stock · 76,200 shares Expires 2033-01-25 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F9 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 76,200 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 9 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,200 shares Expires 2033-01-25 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F9 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 124,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 8 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2032-01-26 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F8 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 124,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 7 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,000 shares Expires 2032-01-26 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F8 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 74,250 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 6 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,250 Underlying: Common Stock · 74,250 shares Expires 2031-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F7 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 74,250 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 5 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,250 shares Expires 2031-01-23 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F7 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 18,198 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 4 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,198 Underlying: Common Stock · 18,198 shares Expires 2030-03-31 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F6 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 18,198 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 3 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,198 shares Expires 2030-03-31 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F6 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 76,047 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,047 Underlying: Common Stock · 76,047 shares Expires 2029-01-24 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cummings Keith LamontChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 76,047 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,047 shares Expires 2029-01-24 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 14 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2035-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 13 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 325,000 shares Expires 2035-01-23 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 256,300 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 12 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,300 Underlying: Common Stock · 256,300 shares Expires 2034-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 256,300 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 11 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 256,300 shares Expires 2034-01-23 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 206,300 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 10 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,300 Underlying: Common Stock · 206,300 shares Expires 2033-01-25 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F9 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 206,300 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 9 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 206,300 shares Expires 2033-01-25 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F9 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 440,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 8 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 440,000 shares Expires 2032-01-26 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F8 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 440,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 7 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 440,000 shares Expires 2032-01-26 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F8 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 6 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F7 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 5 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2031-01-23 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F7 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 327,262 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 4 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,262 Underlying: Common Stock · 327,262 shares Expires 2030-03-31 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F6 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 327,262 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 3 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 327,262 shares Expires 2030-03-31 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F6 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 146,841 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 2 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,841 Underlying: Common Stock · 146,841 shares Expires 2029-01-24 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F3 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Coulie BernardDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 146,841 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001746473-26-000053 · wk-form4_1776458555.xml · derivative · entry 1 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 146,841 shares Expires 2029-01-24 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. F3 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Kuo MinnieChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 55,200 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000055 · wk-form4_1776458567.xml · derivative · entry 6 Kuo Minnie · CIK 0002101360 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,200 Underlying: Common Stock · 55,200 shares Expires 2035-01-23 F3 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F4 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Kuo MinnieChief Operating Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 55,200 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000055 · wk-form4_1776458567.xml · derivative · entry 5 Kuo Minnie · CIK 0002101360 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,200 shares Expires 2035-01-23 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Kuo MinnieChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000055 · wk-form4_1776458567.xml · derivative · entry 4 Kuo Minnie · CIK 0002101360 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-01-23 F3 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F4 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Kuo MinnieChief Operating Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001746473-26-000055 · wk-form4_1776458567.xml · derivative · entry 3 Kuo Minnie · CIK 0002101360 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2034-01-23 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Kuo MinnieChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000055 · wk-form4_1776458567.xml · derivative · entry 2 Kuo Minnie · CIK 0002101360 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-09-14 F3 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F4 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Kuo MinnieChief Operating Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001746473-26-000055 · wk-form4_1776458567.xml · derivative · entry 1 Kuo Minnie · CIK 0002101360 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2033-09-14 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cheung LilyChief Human Resource Officer
|
GrantStock Option (Right to Buy) · Derivative | 51,750 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000052 · wk-form4_1776458549.xml · derivative · entry 6 Cheung Lily · CIK 0001962207 · Chief Human Resource Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,750 Underlying: Common Stock · 51,750 shares Expires 2035-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cheung LilyChief Human Resource Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 51,750 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000052 · wk-form4_1776458549.xml · derivative · entry 5 Cheung Lily · CIK 0001962207 · Chief Human Resource Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,750 shares Expires 2035-01-23 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cheung LilyChief Human Resource Officer
|
GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000052 · wk-form4_1776458549.xml · derivative · entry 4 Cheung Lily · CIK 0001962207 · Chief Human Resource Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2034-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cheung LilyChief Human Resource Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001746473-26-000052 · wk-form4_1776458549.xml · derivative · entry 3 Cheung Lily · CIK 0001962207 · Chief Human Resource Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,000 shares Expires 2034-01-23 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cheung LilyChief Human Resource Officer
|
GrantStock Option (Right to Buy) · Derivative | 123,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000052 · wk-form4_1776458549.xml · derivative · entry 2 Cheung Lily · CIK 0001962207 · Chief Human Resource Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,000 Underlying: Common Stock · 123,000 shares Expires 2033-01-19 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 23, 2023 from January 18, 2033 to the correct expiration date of January 19, 2033. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC |
Cheung LilyChief Human Resource Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 123,000 | $0.00 Strike: $21.94 | $0.00 |
DisclosureSEC source: 0001746473-26-000052 · wk-form4_1776458549.xml · derivative · entry 1 Cheung Lily · CIK 0001962207 · Chief Human Resource Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 123,000 shares Expires 2033-01-19 F1 · kind: On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 23, 2023 from January 18, 2033 to the correct expiration date of January 19, 2033. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:36 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001746473-26-000020 · wk-form4_1769463411.xml · derivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.